3.64
+0.235(+6.91%)
Currency In USD
| Previous Close | 3.4 |
| Open | 3.43 |
| Day High | 3.66 |
| Day Low | 3.41 |
| 52-Week High | 11.88 |
| 52-Week Low | 3.25 |
| Volume | 289,815 |
| Average Volume | 1.74M |
| Market Cap | 256.59M |
| PE | -2.13 |
| EPS | -1.71 |
| Moving Average 50 Days | 3.96 |
| Moving Average 200 Days | 5.33 |
| Change | 0.24 |
If you invested $1000 in C4 Therapeutics, Inc. (CCCC) since IPO date, it would be worth $142.6 as of February 05, 2025 at a share price of $3.635. Whereas If you bought $1000 worth of C4 Therapeutics, Inc. (CCCC) shares 3 years ago, it would be worth $156.48 as of February 05, 2025 at a share price of $3.635.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
C4 Therapeutics Announces 2025 Milestones Across Clinical Portfolio of Degrader Medicines Pursuing Targets of High Unmet Need in Oncology
GlobeNewswire Inc.
Jan 14, 2025 12:00 PM GMT
Cemsidomide Data Presented at American Society of Hematology (ASH) Annual Meeting Support Best-in-Class Profile; Program Advancing to Next Phase of Clinical Development in Multiple Myeloma and Non-Hodgkin’s Lymphoma CFT1946 Phase 1 Trial Continues to
C4 Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Jan 08, 2025 12:00 PM GMT
WATERTOWN, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that Andrew Hirsch, president an
C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 Degrader
GlobeNewswire Inc.
Dec 08, 2024 5:30 PM GMT
In Multiple Myeloma, Cemsidomide in Combination with Dexamethasone at Highest Dose Level Explored to Date Achieved 36 Percent Overall Response Rate (ORR) and 45 Percent Clinical Benefit Rate (CBR); Responses Seen Across All Dose Levels Multiple Myelo